---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-125884"
form_type: "8-K"
ticker: "KALA"
cik: "0001479419"
company_name: "KALA BIO, Inc."
filed_at: "2022-12-09T23:59:59+00:00"
generated_at: "2026-06-21T06:45:06.483432+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Kala Pharma receives Nasdaq deficiency for MVPHS < $15M; faces delisting by Jan 2, 2023

## Summary
- On Dec 5, 2022, Nasdaq notified Kala that market value of publicly held shares was below $15M for 30 consecutive business days.
- Company has 180 days (until June 5, 2023) to regain compliance; needs MVPHS >= $15M for 10 consecutive days.
- Prior July 2022 deficiency for failing multiple Global Select Market standards; must cure by Jan 2, 2023 or face delisting.
- Kala may transfer to Nasdaq Capital Market if compliance not regained; remains out of compliance with Rule 5450(b).

## SEC filing metadata
- accession: 0001104659-22-125884
- form_type: 8-K
- ticker: KALA
- cik: 0001479419
- company_name: KALA BIO, Inc.
- filed_at: 2022-12-09T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1479419/000110465922125884/0001104659-22-125884-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1479419/000110465922125884/tm2232346d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-125884
- JSON: https://secwatch.observer/filing/0001104659-22-125884.json
- Plain text: https://secwatch.observer/filing/0001104659-22-125884.txt

## Key facts
- Listing & Compliance Notices
  KALA BIO, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(C), 5810(c)(3)(D)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: market value
  - Rules: 5450(b)(2)(C), 5810(c)(3)(D)
  source text: December 5, 2022, Kala Pharmaceuticals, Inc. (the “Company”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that the listing of its common stock was not in compliance with Nasdaq Listing Rule 5450(b)(2)(C) (the “Minimum MVPHS Requirement”) for continued listing on the Nasdaq Global Select Market, as the market value of the Company’s publicly held shares was less than $15,000,000 for each of the previous 30 consecutive business days. In accordance with Nasdaq Listing Rule 5810(c)(3)(D), the Compan
  evidence_url: https://www.sec.gov/Archives/edgar/data/1479419/000110465922125884/0001104659-22-125884-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.